Short Code 81801 Texting Information
Information about the company:
Serina Therapeutics is a clinical-stage biotechnology company based in Huntsville, Alabama, at the HudsonAlpha Institute for Biotechnology. Founded in the mid-2000s, Serina has developed a proprietary drug delivery platform based on poly(2-oxazoline), or POZ, polymers. This technology offers a next-generation alternative to PEGylation for improving drug delivery and pharmacokinetics. The POZ platform enables the precise attachment of therapeutic molecules through click chemistry and is designed to enhance solubility, reduce immunogenicity, allow for programmable drug release, and provide room-temperature stability. Importantly, it does not accumulate in tissue and is cleared renally, making it suitable for a wide range of therapeutic applications, particularly in the central nervous system.
The company’s pipeline is centered on neurological disorders, with a strong emphasis on Parkinson’s disease. One of its leading candidates, SER-252, is a POZ-conjugated apomorphine intended for the treatment of advanced Parkinson’s and is currently in the IND-enabling stage, with clinical trials expected in 2025. Another program, SER-214, a POZ-conjugated rotigotine, has completed Phase 1a trials. Additional preclinical programs explore POZ-conjugated cannabinoids for CNS conditions and cardiovascular therapeutics. Serina is also actively pursuing applications in RNA therapeutics and antibody-drug conjugates (ADCs) through strategic collaborations.
Sample text messages:
BULLSEYE (Nyse: SER) *BREAKOUT TIME* Momentum is Building Watch SER Next Move Now READ https://ptxt.io/dcimz *promoted disclaimer in link TxtStop2End
Information and details for Short Code 81801
